Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria

Hepatology

Volumn 61, Issue 1, 2015, Pages 227-237

  Lim, Kheng Choon ^a   Wang, Vivian W ^b   Siddiqui, Fahad J ^a,c   Shi, Luming ^a,d   Chan, Edwin S Y ^a,c   Oh, Hong Choon ^b   Tan, Say Beng ^a   Chow, Pierce K H ^a,e,f  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b Singapore Health Services   (Singapore)

^c SINGAPORE CLINICAL RESEARCH INSTITUTE   (Singapore)

^d MINISTRY OF HEALTH   (Singapore)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CADAVER DONOR; CADAVERIC LIVER TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CHILD PUGH SCORE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; FOLLOW UP; HIDDEN MARKOV MODEL; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; SINGAPORE; SWITZERLAND; CARCINOMA, HEPATOCELLULAR; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; LIVER NEOPLASMS; MIDDLE AGED; STATISTICAL MODEL; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; SINGAPORE; SWITZERLAND; UNITED STATES;

EID: 84921026730     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27135     Document Type: Article

References (63)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Cherqui D, Laurent A, Mocellin N, Tayar C, Luciani A, Van Nhieu JT, et al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009;250:738-746.
3. Del Gaudio M, Ercolani G, Ravaioli M, Cescon M, Lauro A, Vivarelli M, et al. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant 2008;8:1177-1185.
4. Concejero A, Chen CL, Wang CC, Wang SH, Lin CC, Liu YW, et al. Living donor liver transplantation for hepatocellular carcinoma: a single-center experience in Taiwan. Transplantation 2008;85:398-406.
5. Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007;13:543-551.
6. Poon R, Fan S, Lo C, Liu C, Wong J. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 2007;245:51-58.
7. Zhou J, Wang Z, Qiu SJ, Huang XW, Sun J, Gu W, et al. Surgical treatment for early hepatocellular carcinoma: comparison of resection and liver transplantation. J Cancer Res Clin Oncol 2010;136:1453-1460.
8. Pelletier S, Fu S, Thyagarajan V, Romero-Marrero C, Batheja M, Punch J, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl 2009;15:859-868.
9. Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg 2012;99:1622-1629.
10. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-1440.
11. van der Hilst CS, Ijtsma AJ, Slooff MJ, Tenvergert EM. Cost of liver transplantation: a systematic review and meta-analysis comparing the United States with other OECD countries. Med Care Res Rev 2009;66:3-22.
12. Naimark D, Krahn M, Naglie G, Redelmeier D, Detsky A. Primer on medical decision analysis: Part 5. Working with Markov processes. Med Decis Making 1997;17:152-159.
13. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
14. Hwang S, Lee SG, Belghiti J. Liver transplantation for HCC: its role: Eastern and Western perspectives. J Hepatobiliary Pancreat Sci 2010;17:443-448.
15. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
16. Northup PG, Abecassis MM, Englesbe MJ, Emond JC, Lee VD, Stukenborg GJ, et al. Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost. Liver Transpl 2009;15:148-162.
17. Beck J, Kassirer J, Pauker S. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982;73:883-888.
18. Fleming KM, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther 2010;32:1343-1350.
19. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
20. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995;21:77-82.
21. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999;29:1311-1316.
22. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
23. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-1635.
24. Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004;40:823-830.
25. Baccarani U, Isola M, Adani GL, Benzoni E, Avellini C, Lorenzin D, et al. Superiority of transplantation versus resection for the treatment of small hepatocellular carcinoma. Transpl Int 2008;21:247-254.
26. Bigourdan JM, Jaeck D, Meyer N, Meyer C, Oussoultzoglou E, Bachellier P, et al. Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation. Liver Transpl 2003;9:513-520.
27. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010;252:903-912.
28. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373-382.
29. Takahashi S, Kudo M, Chung H, Inoue T, Nagashima M, Kitai S, et al. Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation. Dig Dis 2007;25:303-309.
30. Tanaka H, Kubo S, Tsukamoto T, Shuto T, Takemura S, Yamamoto T, et al. Recurrence rate and transplantability after liver resection in patients with hepatocellular carcinoma who initially met transplantation criteria. Transplant Proc 2005;37:1254-1256.
31. Taura K, Ikai I, Hatano E, Yasuchika K, Nakajima A, Tada M, et al. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients. Surgery 2007;142:685-694.
32. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
33. Llovet J, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10:S115-S120.
34. Omata M, Lesmana L, Tateishi R, Chen P-J, Lin S-M, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. 2010:439-474.
35. Bellavance E, Lumpkins K, Mentha G, Marques H, Capussotti L, Pulitano C, et al. Surgical management of early-stage hepatocellular carcinoma: resection or transplantation? J Gastrointest Surg 2008;12:1699-1708.
36. Cha C, Ruo L, Fong Y, Jarnagin W, Shia J, Blumgart L, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 2003;238:315-321; discussion 321-313.
37. Itamoto T, Nakahara H, Tashiro H, Ohdan H, Hino H, Ochi M, et al. Indications of partial hepatectomy for transplantable hepatocellular carcinoma with compensated cirrhosis. Am J Surg 2005;189:167-172.
38. Sakaguchi T, Suzuki S, Morita Y, Oishi K, Suzuki A, Fukumoto K, et al. Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria. Surg Today 2010;40:638-645.
39. Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y, et al. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. J Hepatobiliary Pancreat Surg 2009;16:359-366.
40. CDC. United States Life Tables. Atlanta, GA: Centers for Disease Control and Prevention; 2008.
41. Vitale A, Boccagni P, Brolese A, Neri D, Srsen N, Zanus G, et al. Progression of hepatocellular carcinoma before liver transplantation: dropout or liver transplantation? Transplant Proc 2009;41:1264-1267.
42. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
43. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011:CD004787.
44. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256-1261.
45. Doffoel M, Bonnetain F, Bouche O, Vetter D, Abergel A, Fratte S, et al. Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402). Eur J Cancer 2008;44:528-538.
46. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
47. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998;29:129-134.
48. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10:534-540.
49. The World Bank. Official exchange rate (LCU per US$, period average). Available from: http://data.worldbank.org/indicator/PA.NUS.FCRF/countries?page=1&display=default: http://data.worldbank.org/indicator/PA.NUS.FCRF/countries?page=1&display=default.
50. United States Department of Labor. Consumer Price Index, Bureau of Labor Statistics. Washington, DC: United States Department of Labor; 2012.
51. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes, 3rd ed. Oxford, UK: Oxford University Press, 2005.
52. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50, 000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8:165-178.
53. World Health Organization. Cost-effectiveness threshold. chooosing interventions that are cost effective (WHO-CHOICE). Geneva, Switzerland: WHO.
54. OECD. Stat extracts. Gross Domestic Product (GDP): GDP per head, US $, current prices, current PPPs. Paris: OECD; 2013.
55. Department of Statistics - Singapore. Time series on per capita GDP at current market prices.
56. Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012;57:675-688.
57. Sarasin F, Giostra E, Mentha G, Hadengue A. Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness perspective. Hepatology 1998;28:436-442.
58. Park Y, Kim B, Wang H, Kim M. Hepatic resection for hepatocellular carcinoma meeting Milan criteria in Child-Turcotte-Pugh class a patients with cirrhosis. Transplant Proc 2009;41:1691-1697.
59. Cillo U, Vitale A, Brolese A, Zanus G, Neri D, Valmasoni M, et al. Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. J Surg Oncol 2007;95:213-220.
60. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000;32:1224-1229.
61. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497-507 e492.
62. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 2011;34:422-431.
63. Li SC, Ong SC, Lim SG, Yeoh KG, Kwong KS, Lee V, et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol 2004;38:S136-143.